Chapter from the book *Ovarian Cancer - A Clinical and Translational Update*
Downloaded from: http://www.intechopen.com/books/ovarian-cancer-a-clinical-and-translational-update

Interested in publishing with InTechOpen? Contact us at book.department@intechopen.com
1. Introduction

Ovarian cancer is currently the fifth most lethal malignancy of women in Europe and the United States [1, 2]. The prognosis of ovarian cancer patients is limited due to lack of specific early symptoms and a high rate of relapse; more than half of all patients will suffer from disease recurrence, resulting in a poor overall survival [3]. Most cases are diagnosed in advanced stages, and although the initial response to chemotherapy is generally good, a significant proportion of patients will suffer from a relapse despite optimal cytoreductive surgery [4]. Since treatment strategies are mainly developed to control locoregional cancer growth, it may be anticipated that more women will die of distant metastatic disease. The identification of novel molecular markers, reflecting current tumor activity, may improve prediction and therapy monitoring and provide valuable insights into process of carcinogenesis. In this regard, oncologic research have increasingly focused on disseminated and circulating tumor cells.

The presence of disseminated tumor cell (DTC) in bone marrow (BM) is a phenomenon observed in almost all solid tumors of epithelial origin. For breast cancer, DTC presence has been demonstrated as a strong independent prognostic factor (level I evidence) [5]. Available data support the notion that hematogenous tumor cell dissemination may be clinically relevant in ovarian cancer as well [6-10]. Detection rates of DTC, as a surrogate parameter for occult hematogenous spread, vary between 30-50% primary ovarian cancer patients.

A provocative hypothesis has been introduced recently with respect to natural history and progression of ovarian cancer. While the 'classical' stochastic model of cancer development holds that any cell may become source of malignant transformation, emerging evidence sup-
ports the view that only a minor subpopulation of cancer cells has the potential to initiate cancer growth. These cells, called cancer stem cells (CSC), have the ability to self-renew, propagate tumorigenesis and are usually drug-resistant [11]. Experimental studies on stem cell biology have given new impetus to the cancer stem cell theory. CSC are assumed to play important role in development of various tumor entities, such as breast and gastrointestinal cancer, retinoblastoma and ovarian cancer [12], [13]. Interestingly, ovarian cancer cell lines feature “side population” cells with potential to differentiate into cancers with different histologies, suggesting the pluripotent character of stem cells [14]. Whether DTC in extraperitoneal sites, such as bone marrow, reflect a stem cell-like sub population of tumor cells, remains yet to be cleared.

Of all prognostic factors, monitoring of minimal residual disease is the only one available after the tumor has been removed. Beside monitoring of tumor markers, there is currently a major effort to identify other biological markers which can be assessed with minimally invasive methods and persist beyond surgery. We previously reported on a significant correlation of positive BM status with shortened relapse-free survival in ovarian cancer patients [6]. DTC persistence after completion of platinum-based chemotherapy was also found to be prognostically relevant [15]. Recently, attempts have been made to target DTC by using antibody-based therapy with the trifunctional antibody catumaxomab. Wimberger et al. reported a marked decrease in tumor cells in peripheral blood following intraperitoneal catumaxomab treatment for malignant ascites, indicating a systemic effect of the therapy [16]. However, in comparison with breast cancer, data on DTC detection in gynecological malignancies are so far limited [7], [17], [18], [19], [9].

In this chapter we discuss recent advances in ovarian cancer research with respect to disseminated tumor cells and cancer stem cell hypothesis. Data on prognostic and clinical relevance are presented.

2. Disseminated and circulating tumor cells in ovarian cancer

Detection and characterization of disseminated tumor cells in bone marrow and blood of patients with epithelial carcinomas can be accomplished by various techniques. For the detection of isolated tumor cells, both antibody-based assays and molecular assays have been established [20, 21]. Despite advances in this field, no specific antigen or marker gene has been described for ovarian cancer so far. Therefore, immunocytochemical identification of these cells based on expression of epithelial markers remains the gold standard (Figure 1). Commonly targeted antigens are cytokeratin and EpCAM due to relatively constant and universal expression pattern in cells of epithelial origin [9, 15, 22]. A major difficulty in detecting and characterizing tumor cells is their relatively low frequency. Most protocols include therefore a cell enrichment step (e.g. density gradient centrifugation, immunomagnetic enrichment). These obstacles highlight the need for optimization of the assay (e.g. by minimizing cell loss, preserving cell morphology and producing reliable immunophenotypic and genotypic data) as it is essential for detecting, enumerating and characterizing single tumor cells [21].
Detection rates of disseminated tumor cells in ovarian cancer patients stage FIGO I-III reach 20-60% [7, 9, 15, 22]. These results suggest hematogenous spread to be a comparatively frequent phenomenon in ovarian malignancies and indicate the ability of single tumor cells to disseminate to bone marrow in a very early stage of disease. DTC are routinely detected in 13-18% FIGO I ovarian cancer patients [6, 19, 22]. Since bone metastases are relatively rare in ovarian cancer patients, BM seems to serve as a temporary ‘homing site’ for single tumor cells, from where they are able to migrate and subsequently cause distant metastasis or local recurrence [24]. Assuming that DTC may spread by means of blood stream we cannot exclude that those may also be able to repopulate the peritoneal cavity, an environment which easily supports ovarian cancer growth [11, 25].

Based on numerous studies, no significant relationship has been reported between clinicopathological characteristics of primary tumor and DTC detection. In our latest trial with 414 ovarian cancer patients, DTC status did not correlate with FIGO stage, tumor size, lymph node status, histopathologic grading or resection status [26, 27]. Braun et al., in a cohort of 108 primary ovarian cancer patients, showed no concordance between classical prognostic factors and DTC positivity. The only factor associated with positive DTC status was tumor grading (p = 0.02) [7]. These results could be also confirmed in our earlier study with 112 ovarian cancer patients [6]. Similar findings were obtained by other investigators [8, 9, 15, 19].
2.1. Prognostic relevance of DTC/CTC in ovarian cancer

Detection of disseminated tumor cells in patients with primary ovarian cancer was shown to be of prognostic value (Table 1). However, the currently available data are sparse. In our latest trial bone marrow status of 414 ovarian cancer patients was correlated with clinical follow-up [26]. The presence of DTC predicted a shorter OS (p < 0.001) and DFS (p = 0.035) compared with BM negative patients [27]; this association was highly significant and confirmed in a multivariable Cox regression analysis. Similar results were found in several smaller studies. Braun et al. demonstrated unfavorable prognosis with regard to distant DFS in BM positive patients at the time of diagnosis [7]. DTC presence remained a strong prognostic factor also in a subset of 64 optimally debulked patients (p = 0.002), which highlights the role of DTC detection especially in patients who received successful surgical cytoreduction. We previously reported a significant correlation of positive BM status with reduced DFS in a group of 112 stage FIGO I-III ovarian cancer patients [6]. Interestingly, in some studies, the presence of isolated tumor cells in secondary sites, such as BM and blood, was also associated with higher risk for recurrence [10], [6]. Therefore, it might be speculated that hematogenous tumor cell dissemination may serve as an indicator of a more aggressive phenotype of the primary disease that is likely to cause local relapse. In contrast, other authors reported no significant correlation between DTC detection and clinical outcome in ovarian cancer [19, 28]. This discrepancy might be due to differences in study protocols, e.g. time point of BM sample collection (pre- vs. postoperative aspiration). Hypothetically, a transient increase in cancer cell dissemination from the primary tumor due to intraoperative manipulation could contribute to false-positive results and therefore affect further analysis [29].

2.2. Circulating tumor cells

Bone marrow biopsy represents an invasive procedure not well tolerated by many patients. Therefore, detection of circulating tumor cells (CTC) by simple blood drawing has increasingly become a focus of translational research. Prognostic significance of CTC in peripheral blood has been evaluated in breast cancer both in primary and metastatic disease [33, 34]. Two commercially available kits are currently in use for CTC detection in blood of breast cancer patients: antibody-based CellSearch and RT-PCR-based AdnaTest. Both assays were modified and validated in ovarian cancer patients (Table 1). Recently published trial by Poveda et al. based on a cohort of 216 patients with recurrent ovarian cancer, represents the largest study so far on the impact of CTC presence on survival [10]. Using CellSearch test increased CTC numbers (> 1 cell / 7.5 ml blood) were found in 14% of these patients before the beginning of treatment. Detection of CTC in peripheral blood was associated with significantly impaired prognosis. In the study by Aktas et al., including 86 ovarian cancer patients, a modified AdnaTest kit was used to detect cells expressing EpCAM, MUC-1, HER-2 or CA 125-transcripts [8]. CTC positivity rate of 19% observed in this cohort was associated with significantly shorter survival independent of the time of blood sampling (before surgery or after chemotherapy). Similar results were obtained by Fan et al. in a trial of 66 primary ovarian cancer patients [32]. In contrast, Marth et al. reported a 12% positivity rate...
irrespective of tumor stage but observed no correlation with clinical outcome [19]. Interestingly, positive finding in the blood was highly associated with DTC detection in bone marrow. Smaller studies showed varying CTC incidence, depending on methodology [35, 36].

<table>
<thead>
<tr>
<th>Author</th>
<th>N</th>
<th>Method</th>
<th>Median follow-up [months]</th>
<th>Positivity rate</th>
<th>Prognostic significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fehm [26]</td>
<td>414</td>
<td>DTC (ICC)</td>
<td>34</td>
<td>27%</td>
<td>OS, DFS ^1</td>
</tr>
<tr>
<td>Banys [6]</td>
<td>112</td>
<td>DTC (ICC)</td>
<td>12</td>
<td>25%</td>
<td>DFS</td>
</tr>
<tr>
<td>Braun [7]</td>
<td>108</td>
<td>DTC (ICC)</td>
<td>45</td>
<td>30%</td>
<td>DFS</td>
</tr>
<tr>
<td>Aktas [8]</td>
<td>95</td>
<td>DTC (ICC)</td>
<td>28</td>
<td>35%</td>
<td>n.s.</td>
</tr>
<tr>
<td>Schindlbeck [9]</td>
<td>90</td>
<td>DTC (ICC)</td>
<td>28</td>
<td>23%</td>
<td>DDFS</td>
</tr>
<tr>
<td>Marth [19]</td>
<td>73</td>
<td>DTC (immunobeads)</td>
<td>25</td>
<td>21%</td>
<td>n.s.</td>
</tr>
<tr>
<td>Wimberger [30]</td>
<td>62</td>
<td>DTC (ICC)</td>
<td>18</td>
<td>54%</td>
<td>DFS ^2</td>
</tr>
<tr>
<td>Poveda [10]</td>
<td>216</td>
<td>CTC (ICC: CellSearch) ^1</td>
<td></td>
<td>14% ^4</td>
<td>PFS, OS</td>
</tr>
<tr>
<td>Sehouli [17]</td>
<td>167</td>
<td>CTC (ICC)</td>
<td>46</td>
<td>n.s.</td>
<td></td>
</tr>
<tr>
<td>Marth [19]</td>
<td>90</td>
<td>CTC (immunomagnetic beads)</td>
<td>25</td>
<td>12%</td>
<td>n.s.</td>
</tr>
<tr>
<td>Aktas [8]</td>
<td>86</td>
<td>CTC (Multiplex-RT-PCR: AdnaTest)</td>
<td>28</td>
<td>19%</td>
<td>OS ^5</td>
</tr>
<tr>
<td>Heubner [31]</td>
<td>68</td>
<td>Circulating 20S-proteasomes</td>
<td>19</td>
<td>-</td>
<td>OS</td>
</tr>
<tr>
<td>Fan [32]</td>
<td>66</td>
<td>CTC (immunofluorescence, cell invasion assay)</td>
<td>18</td>
<td>61%</td>
<td>DFS</td>
</tr>
<tr>
<td>Wimberger [30]</td>
<td>62</td>
<td>Circulating nucleosomes, DNA, protease and caspase activity</td>
<td>18</td>
<td>-</td>
<td>DFS, OS</td>
</tr>
</tbody>
</table>

Abbreviations: DFS – disease-free survival, DDFS – distant disease-free survival, DTC – disseminated tumor cells in bone marrow, ICC – immunocytochemistry, n.s. – not significant, PFS – progression-free survival

^1 Determined by multivariate Cox regression analysis
^2 DTC detected after chemotherapy
^3 Relapsed ovarian cancer
^4 Two or more CTC
^5 Both before and after chemotherapy

Table 1. Prognostic relevance of disseminated and circulating tumor cells in ovarian cancer.

2.3. Therapy monitoring

Beyond the prognostic value of DTC/CTC detection, monitoring of minimal residual disease (MRD) during and after treatment offers the opportunity to assess response to therapy and evaluate the residual risk of recurrence. Changes in MRD represent the only clinical parame-
ter available after surgical removal of the primary tumor. While tumor markers are established tools for the evaluation of treatment efficacy in patients with advanced ovarian cancer, CA 125 levels fall during adjuvant chemotherapy and remain often below cut-off values after completion of first line systemic treatment even though significant number of patients will suffer from relapse within five years. Furthermore, the clinical relevance of serial CA125 measurements for early detection and treatment of disease recurrence is currently being controversially discussed [37]. In this regard, the detection of isolated tumor cells in bone marrow or peripheral blood might serve as a parameter for occult tumor load after completion of first line therapy. DTC persistence despite adjuvant treatment is so far an independent prognostic factor in patients with primary breast cancer [38]. Whether persistent DTC influence prognosis in ovarian cancer patients, is currently being investigated. In the study by Wimberger et al. DTC counts before and after the first line systemic treatment were correlated to clinical course of disease in 30 ovarian cancer patients; 54% of these patients presented with DTC after first-line chemotherapy. Marked increase in DTC counts was associated with shortened progression free survival [15].

Evaluation of treatment efficacy in ovarian cancer patients after optimal surgical cytoreduction and completion of first line systemic therapy is based on clinical, radiological and biological (tumor marker CA125) criteria. However, a reliable tool to assess long-term prognosis has so far not been established. Therefore, a solid therapy monitoring tool could help to identify a group of high-risk patients who potentially benefit from additional treatment. New studies are required to evaluate whether persistent DTC indeed predict a worse prognosis and if these cells may be targeted by secondary adjuvant therapy.

3. Cancer stem cell model

An important hypothesis on tumor initiation and progression has attracted much attention in the ovarian cancer research in the past decade. In contrast to stochastic model that postulates every cell as a potential source of malignant transformation, the cancer stem cell model, a theory introduced over a century ago, proposes that tumors are organized in a cellular hierarchy, in which cancer stem cell (CSC) are the only cells with tumorigenic potential. Accordingly, tumors are initiated in cancer stem cells or their immediate progeny through imbalance of self-renewal and apoptosis; these tumors contain a cellular subpopulation that retains key stem cell feature [39]. This small cell group with unlimited proliferative potential is assumed to play a marked role in initiation and development of several tumor entities like retinoblastoma, gastrointestinal cancer as well as breast and ovarian cancer [12]. The cancer stem cell concept has important implications for understanding the process of carcinogenesis as well as for designing new treatment strategies. Due to their long life, CSC are more likely to acquire transforming mutations; further, they seem more resistant to apoptosis and DNA damage and are therefore able to persist beyond therapy. New evidence in support of the cancer stem cell model has arisen due to advances in stem cell biology and the introduction of novel animal models to assess self-renewal and challenge the validity of this concept.
The cancer stem cell hypothesis holds that CSC are responsible for phenomena like drug resistance, tumor dormancy or minimal residual disease and may persist beyond chemotherapy and repopulate the tumor leading to relapse [11]. The stem cell subpopulation, but not the remaining differentiated cancer cells in the tumor, can sustain tumor formation and growth due to their high tumor-initiating potential. So far, such cells have been found in several solid tumors, such as colon [40], breast [41] and ovarian cancer [13, 42, 43]. Indeed, in accordance with recent studies, ovarian cancer cell lines feature ‘side population’ cells (SP) with potential to differentiate into other morphological entities. Thus, this pluripotent subclone with stem cell-like features is considered a marker of CSC presence [14]. The detection of CSC is based on the presence of extracellular markers assumed to be stem cell-specific; commonly identified markers are CD44, CD133, and CD24, which are found in prostate, breast, pancreas, and ovarian cancer. It remains under discussion whether these parameters are universal markers relevant for CSC derived from all tumor types; for ovarian cancer, multiple markers have been described for the stem cell-like tumor initiating cells.

Owing to aggressive natural course of disease and emergence of multidrug resistance, an essential role of cancer stem cells has been postulated in ovarian cancer [13, 44]. In the study by Szotek et al. SP cells have been encountered in ovarian cancer cell lines as well as in primary ascites cancer cells [13]. In the trial by Hosonuma et al. in 18 of 28 ovarian cancer patients samples side population cells could be detected. SP cells occurred more often in relapsed and metastatic patients and SP positivity predicted significantly reduced overall survival [15]. A high proportion of CD44+ stem cells in ovarian cancer was reported to be an independent predictor of poor progression-free survival [45].

As previously mentioned, CSC are considered responsible for high emergence of drug resistance in the natural history of ovarian cancer, since standard therapies fail to target pluripotent tumor-initiating cells [13]. Latifi et al. could show in their recently published trial, the ability of cisplatin chemotherapy to generate residual tumor cells with mesenchymal stem cell-like characteristics in vitro [46]. Accordingly, new therapeutic strategies have to be developed to target these cells by identifying their specific antigens. However, very few tumor characteristics have been described to target the subset of CSC.

Based on an animal model, Bapat et al. reported the isolation and identification of ovarian cancer stem cells [42]. In an in vitro model comprised of 19 spontaneously immortalized clones derived from an advanced-stage patient, the authors demonstrated the ability of two clones with stem cell-like characteristics to differentiate to grow as spheroids and form xenografts in an animal model (nude mice). These cells were shown to express CD44, E-cadherin, and the stem cell factors Nestin, Nanong, and Oct-4.

3.1. DTC and cancer stem cell model

A currently discussed theory postulate DTC and CTC, the presumed precursor cells of systemic metastatic disease, to be in fact cancer stem cells. These observations have been so far reported in breast cancer studies. Balic et al. analyzed bone marrow specimens from 50 primary breast cancer patients; 33-100% of DTC of every patient exhibited stem cell-like phenotype: CD44+ / CD24 low/- [47]. This prevalence is estimated for less than 10% in primary
tumor suggesting much higher, stem cell like self-renewal and tumorigenic potential in
DTC. Aktas et al. detected stem cells markers on CTC in peripheral blood of metastatic
breast cancer patients [41]. Moreover, Abraham et al. reported that high proportion of stem
cell-like subpopulation in primary breast cancer correlate with a higher prevalence of dis‐
tant metastases [48]. As breast cancer stem cells have been shown to be generally triple-neg‐
ative, basal-like CTC, independent of the phenotype of the primary tumor, support the
cancer stem cell theory [20, 49, 50]. However, this aspect has not been researched in ovarian
cancer so far. Therefore, futher studies have to be performed to evaluate whether isolated
tumor cells in extraperitoneal sites, such as blood and bone marrow, may reflect ovarian
cancer stem cell population.

4. Conclusions

Despite advances in surgical and systemic therapy, ovarian cancer leads to relapse in 60% of
patients within 5 years, resulting in impaired clinical outcome. In the last decades, novel bio‐
markers have been introduced for better prediction and prognostication [51]. Early hema‐
togenous dissemination of single tumor cells is a general phenomenon observed in most
solid tumors of epithelial origin; recent data supports the clinical relevance of disseminated
and circulating tumor cells (DTC/CTC) in ovarian cancer. A currently discussed hypothesis
postulates isolated tumor cells in secondary sites to be not only the presumed precursors of
systemic metastatic disease but in fact pluripotent ‘cancer stem cells’. Future research will
clarify the implications of these findings for clinical management of ovarian cancer patients.
While the published data do not support the use of DTC/CTC detection for early detection
or screening purposes, its role as an important prognostic factor has been confirmed in sev‐
eral studies. One of the most promising applications of DTC detection is their use as a thera‐
py monitoring tool. DTC persistence beyond surgery and adjuvant chemotherapy may help
to identify patients at risk of developing a relapse.

Author details

Malgorzata Banys, Natalia Krawczyk, Andreas D. Hartkopf and Tanja Fehm*

*Address all correspondence to: tanja.fehm@t-online.de

1 Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany
2 Department of Obstetrics and Gynecology, Marienkrankenhaus Hamburg, Hamburg, Ger‐
many
References


